Leap Ahead With EAP? FDA Proposes New Expedited PMA Pathway
This article was originally published in The Pink Sheet Daily
Executive Summary
The newly proposed “expedited access” PMA program combines early and outsized interactions between reviewers and manufacturers with the promise of lightened premarket requirements for selected products – if the potential pay off to patients is large enough and postmarket controls are sufficient.